---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-24-000160"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:24:57.742009+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M

## Summary
- Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).
- Decipher revenue +48%, volume +36% (21,250 tests); Afirma revenue +19%, volume +12% (15,100 tests).
- GAAP net income $15.2M; adjusted EBITDA $27.3M (24% margin); operating cash flow $30.0M.
- Presented Decipher Prostate clinical data from STAMPEDE (ESMO) and VANDAAM (ASTRO); added two directors and SVP of Operations.

## SEC filing metadata
- accession: 0001384101-24-000160
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000160/0001384101-24-000160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000160/vcyt-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-24-000160
- JSON: https://secwatch.observer/filing/0001384101-24-000160.json
- Plain text: https://secwatch.observer/filing/0001384101-24-000160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.